Optimi Health Corp. (OPTH) Form 6-K — Jun 8, 2026
Optimi Health Corp. (OPTH) announced it has secured naturally derived ibogaine from two sources and will commence development of finished drug products at its GMP facility in British Columbia this summer. The company plans to produce 50mg and 100mg encapsulated dosages, leveraging its existing infrastructure for psilocybin and MDMA manufacturing. This move follows a US Executive Order signed in April 2026 that prioritized ibogaine compounds for accelerated FDA review and expanded patient access.
Key figures
- Dosage sizes
- ["50mg","100mg"]
- Texas funding program
- $50 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.